Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Jean Chastre(Inserm), Tomas Hruby, Vincent Huberlant(Centre Hospitalier Universitaire de Nantes), Herman Goossens(University of Antwerp), Drieke Vandamme(Inserm), Ahmad Akhgar(AstraZeneca (United States)), Julien Sauser(University Hospital of Geneva), Despoina Koulenti(University of Thessaly), Alexey Ruzin(AstraZeneca (United States)), Leen Timbermont(Ghent University), Miguel Sánchez García(Hospital Clínico San Carlos), Terramika Bellamy(AstraZeneca (United States)), Michael Joannidis(Innsbruck Medical University), Olivier Barraud(Inserm), Ricard Ferrer(Universitat Autònoma de Barcelona), Surbhi Malhotra‐Kumar(University of Antwerp), Jacques Devriendt(Centre Hospitalier Universitaire Brugmann), Frank E. J. Coenjaerts(Utrecht University), David E. Tabor(AstraZeneca (United States)), İftihar Köksal(Karadeniz Technical University), Charles‐Édouard Luyt(Inserm), Antonio Oliver(Health Research Institute of the Balearic Islands), Pieter Depuydt(Ghent University Hospital), Michal Hanauer, Marc J. M. Bonten(Utrecht University), Thomas L Holland(Duke University), Jasminka Kopić, Alain Lepape(Hospices Civils de Lyon), Pin Ren(AstraZeneca (United States)), Sam Van Boxstael, Kathryn Shoemaker(AstraZeneca (United States)), Hasan S. Jafri(AstraZeneca (Australia)), Nicolas De Schryver(Clinique Saint Pierre), Susan Colbert(AstraZeneca (United States)), Philippe Eggimann(University Hospital of Lausanne), Marc Bourgeois(AZ Sint-Jan), Antonio DiGiandomenico(AstraZeneca (United States)), Colin Reisner(Reproductive Medicine Associates of New Jersey), Mark T. Esser(AstraZeneca (United States)), Omar Ali(AstraZeneca (United States)), Walter Klimscha, Antoní Torres(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Bruno François(Inserm), Yuling Wu(AstraZeneca (United States)), Galia Rahav(Tel Aviv University), Mladen Perić, Elisabeth De Waele(Vrije Universiteit Brussel), Yu Jiang(AstraZeneca (United States)), Apostolos Komnos(University Hospital of Larissa)
Cited by 93
Related Papers
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Critical Care Medicine|2017|3.8k